p53/Rb Pathway Mutation PCR Array

qBiomarker Somatic Mutation PCR Array: Human p53/Rb The Human p53/Rb Pathway qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, accurate, and comprehensive profiling of the somatic mutation status for key genes in the p53 and Rb pathways: ATM, CDKN2A, Rb, and TP53. Components in these tumor suppressor pathways are frequently mutated in human cancers, are associated with resistance to multiple chemo-therapeutic drugs, and frequently predict prognosis. Mutations in these pathways therefore warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. The utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions has been demonstrated in numerous research studies. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human p53/Rb Pathway qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for studying mutations in the context of the p53/Rb pathways and provides the potential to discover and verify drug target biomarkers for a variety of human cancers involving the p53/Rb tumor suppressor pathways and downstream effectors. This array includes 90 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in the p53/Rb pathways. These mutations were chosen from curated, comprehensive, somatic mutation databases and peer-reviewed scientific literature. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments. The qBiomarker Somatic Mutation PCR Arrays are intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.

Assay Functional Annotations

How It Works

References

Resources

Modify this Array    ATM gene: Included on the panel are 6 most commonly detected ATM loss-of-function mutations that occur in the FAT, FATC and the kinase domains. CDKN2A gene: Included on the panel are the top 9 CDKN2A loss-of-function mutations that occur in the consensus ankyrin domain, which leads to inability to form stable complexes with its targets. RB gene: Included on the panel are 3 highly recurrent RB loss of tumor suppressor mutations that are either due to truncation or disruption of binding partner interactions. TP53 gene: Included on the panel are 72 most frequently detected somatic mutations on the TP53 gene, which are largely composed of DNA-binding domain mutations which either disrupts contact with DNA or the structure of the protein.

Assay Functional Annotations

How It Works

References

Resources

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol. The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples. Principle of Mutant Discrimination with ARMS® Back to Top

Assay Functional Annotations

How It Works

References

Resources

The PKB/AKT pathway in cancer.Carnero A. Curr Pharm Des. 2010 Jan; 16(1):34-44 BRAF, a target in melanoma: implications for solid tumor drug development. Flaherty KT, McArthur G. Cancer. 2010 Jul 13. [Epub ahead of print] Clinical relevance of KRAS in human cancers. Jancík S, Drábek J, Radzioch D, Hajdúch M. J Biomed Biotechnol. 2010; 2010:150960. Oncogenic Ras in tumour progression and metastasis. Giehl K. Biol Chem. 2005 Mar; 386(3):193-205 MEK1 mutations confer resistance to MEK and B-RAF inhibition. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA. Proc Natl Acad Sci U S A. 2009 Dec 1; 106(48):20411-6 PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M. Cell Cycle. 2009 May 1; 8(9):1352-8 Oncogenic mutations as predictive factors in colorectal cancer. Lièvre A, Blons H, Laurent-Puig P. Oncogene. 2010 May 27; 29(21):3033-43  PI(3)King Apart PTEN's Role in Cancer. Zhang S, Yu D. Clin Cancer Res. 2010 Jul 8. [Epub ahead of print] Back to Top

Assay Functional Annotations

How It Works

References

Resources

User Manual qBiomarker Somatic Mutation PCR Array System (PDF) Data Analysis qBiomarker Somatic Mutation PCR Array Data Analysis Software Application Data Detection Limits, Cancer Pathways FAQ Frequently Asked Questions about Somatic Mutation Assays and Arrays Webinar qBiomarker Somatic Mutation Analysis: Real-World Application Data Slide Presentation> Presentation about qBiomarker Somatic Mutation Assays and Arrays (PDF) Scientific Poster A Novel Tool for Pathway-Focused Cancer Mutation Profiling (PDF) Presented at American Association for Cancer Research 2011 White Paper Rapid and accurate cancer somatic mutation profiling with the qBiomarker Somatic Mutation PCR Array (PDF) Product Profile For screening biology-focused panels of gene mutations (PDF) Back to Top